FDA Panel Gives Nod to New Blincyto Use in ALL FDA Panel Gives Nod to New Blincyto Use in ALL
Blinatumomab would become the first treatment for which minimal residual disease positivity would be a selection criterion and MRD negativity an endpoint for acute lymphoblastic leukemia.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Health | Hematology | Leukemia